As of Aug 28
| +0.03 / +1.54%|
The 3 analysts offering 12-month price forecasts for Pluristem Therapeutics Inc have a median target of 6.00, with a high estimate of 8.00 and a low estimate of 4.00. The median estimate represents a +203.03% increase from the last price of 1.98.
The current consensus among 3 polled investment analysts is to Buy stock in Pluristem Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.